<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749927</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0951</org_study_id>
    <nct_id>NCT04749927</nct_id>
  </id_info>
  <brief_title>Deep Learning of Retinal Photographs and Atherosclerotic Cardiovascular Disease</brief_title>
  <official_title>Prediction of Incident Atherosclerotic Cardiovascular Disease From Retinal Photographs Via Deep Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research team has developed a deep learning algorithm that predicts anthropometric&#xD;
      factors from fundus photographs and an algorithm that predicts cardiovascular disease risk.&#xD;
      Fundus photographs are taken for various cardiovascular diseases (myocardial infarction,&#xD;
      heart failure, hypertension with target organ damage, high-risk dyslipidemia, diabetic&#xD;
      patients, and low-risk hypertension patients), and a deep learning algorithm for predicting&#xD;
      developed anthropometric factors will be validated. Fundus photographs will also be taken&#xD;
      twice in the first year, and additional fundus photographs will be taken two years later.&#xD;
      Major cardiovascular events will be followed up for 5 years to verify the deep learning&#xD;
      algorithm predicting cardiovascular disease risk prospectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2020</start_date>
  <completion_date type="Anticipated">October 10, 2029</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular disease</measure>
    <time_frame>4 years</time_frame>
    <description>Composite of myocardial infarction, stroke, coronary revascularization including percutaneous coronary intervention and coronary bypass graft, and hospitalization for heart failure</description>
  </primary_outcome>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Cardiovascular Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Visiting outpatient clinic in the tertiary hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Myocardial infarction (Patients diagnosed with myocardial infarction within 5 years&#xD;
             and confirmed significant coronary artery stenosis by cardiovascular angiography)&#xD;
&#xD;
          2. Heart failure with reduced EF (&lt;40% of LVEF on echocardiography or magnetic resonance&#xD;
             imaging)&#xD;
&#xD;
          3. Heart failure with preserved EF (≥40% of LVEF on echocardiography and NT-proBNP ≥200&#xD;
             pg/mL and LAVI ≥ 34 ml/m2 or LVMI ≥115 g/m2 (men) or LVMI ≥95 g/m2 (women))&#xD;
&#xD;
          4. High risk subclinical atherosclerosis (no symptom and ≥50% stenosis of coronary artery&#xD;
             on coronary angio CT or asymptomatic PAOD or cerebral aneurysm or ≥50% stenosis of&#xD;
             cerebral artery or ABI &lt;0.9 or ≥2mm of atherosclerotic plaque or hypoechogenic plaque&#xD;
             on carotid ultrasound)&#xD;
&#xD;
          5. Hypertension with target organ damage (proteinuria [urine albumin/creatinine ratio ≥&#xD;
             30 mg/g or protein/creatinine ratio ≥ 150 mg/g or 24 hour urine albumin ≥30mg/day or&#xD;
             24 hour urine protein ≥ 150mg/day] or LV hypertrophy [on EKG or echocardiography] or&#xD;
             cfPWV &gt; 10 m/sec or baPWV &gt; 1800 cm/sec or eGFR &lt; 60 ml/min/1.72 m2 or atherosclerotic&#xD;
             cardiovascular disease or white matter hyperintensity on brain MRI)&#xD;
&#xD;
          6. High risk dyslipidemia (LDL-cholesterol &gt;190 mg/dL or &gt; 160 mg/dL inspire of use of&#xD;
             moderate or high intensity statin)&#xD;
&#xD;
          7. Diabetes (Type 2 diabetes with more than 5 years of diagnosis or type 1 diabetes with&#xD;
             more than 10 years of diagnosis)&#xD;
&#xD;
          8. Low risk (Hypertension that does not meet the above criteria and is controlled by 3&#xD;
             drugs or less 2) Dyslipidemia that does not meet the above criteria and is controlled&#xD;
             below the target LDL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious eye diseases that make it impossible to take adequate quality fundus&#xD;
             photography&#xD;
&#xD;
          2. If the subject cannot read and sign the consent form in person&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sungha Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sungha Park</last_name>
    <phone>+82-2228-8460</phone>
    <email>shpark0530@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungha Park</last_name>
      <phone>+82-2228-8460</phone>
      <email>shpark0530@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

